Copyright © 2015, Evaluate Ltd, All rights reserved.
EvaluatePharma World Preview 2015, Outlook to 2020
Worldwide Rx Sales Forecast to Grow 5% p.a. to 2020

Download your copy of World Preview 2015, Outlook to 2020

Download the eighth edition of the EvaluatePharma® World Preview 2015, Outlook to 2020 report which brings together many of our analyses to provide a top level insight, from the world's financial market, into the expected performance of the industry between now and 2020.

If there was any doubt that the pharmaceutical industry is entering a period of sustained growth it should be put to rest by this report showing prescription drug sales are set to advance at almost 5% a year until 2020.

Key highlights include:

  • Worldwide Rx drug sales to reach almost $1 trillion by 2020
  • Key prescription drug sales jumped 4.9% in 2014
  • Industry's R&D pipeline valued at $493bn
  • Humira remained top-selling product in 2014 with $13bn in sales
  • The US FDA approved a record number of new drugs in 2014
  • AbbVie's Humira to account for 25%+ of the anti-rheumatic market in 2020
  • Gilead to dominate the anti-viral segment in 2020

Please confirm your details to download your copy of this report.

Download your copy of World Preview 2015, Outlook to 2020

 

You can now download the World Preview 2015 Excel Data Pack -  complete the form to download the data pack.

Download the eighth edition of the EvaluatePharma® World Preview 2015, Outlook to 2020 report which brings together many of our analyses to provide a top level insight, from the world's financial market, into the expected performance of the industry between now and 2020.

If there was any doubt that the pharmaceutical industry is entering a period of sustained growth it should be put to rest by this report showing prescription drug sales are set to advance at almost 5% a year until 2020.
 

Key highlights in EvaluatePharma® World Preview 2015, Outlook to 2020 include:

  • Worldwide prescription drug sales are expected to reach almost $1 trillion by 2020 (CAGR: 4.8% between 2014 and 2020)
  • Key prescription drug sales jumped 4.9% in 2014, driven by an 8.9% surge in USA sales; Europe returns to growth at 2.4%; Japan slumps 2.6% in yen
  • Industry's R&D pipeline valued at $493bn; Gilead's potential new combination hepatitis C product most valuable
  • Humira remained the top-selling product in 2014 with sales of $13bn; Sovaldi debuts at number two with sales of $10bn
  • A record number of new drugs were approved by the US FDA in 2014; sales potential increases by 45%
  • AbbVie's Humira continues to account for over 25% of the anti-rheumatic market in 2020
  • Gilead continues to dominate the anti-viral segment in 2020 capturing over 50% of the entire market

Please confirm your details on the opposite form to download your complimentary copy of this report.

Download World Preview 2015

EvaluatePharma® is the trusted leader in consensus forecasts of leading industry analysts and analysis of the pharmaceutical and biotechnology healthcare sectors providing exclusive and trusted market intelligence into global performance to 2020. Find out more.

Every year we publish our World Preview report and make it available to industry free of charge. Over the years, it has become a much anticipated industry standard of annual sector performance and forecasts. We thank our readership and clients for their interest in the World Preview and for spreading the word about it.